ZA200701554B - Sustained release pharmaceutical particulate compositio comprising venlafaxine - Google Patents
Sustained release pharmaceutical particulate compositio comprising venlafaxine Download PDFInfo
- Publication number
- ZA200701554B ZA200701554B ZA200701554A ZA200701554A ZA200701554B ZA 200701554 B ZA200701554 B ZA 200701554B ZA 200701554 A ZA200701554 A ZA 200701554A ZA 200701554 A ZA200701554 A ZA 200701554A ZA 200701554 B ZA200701554 B ZA 200701554B
- Authority
- ZA
- South Africa
- Prior art keywords
- venlafaxine
- dispersion
- composition
- particles
- sustained release
- Prior art date
Links
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 229960004688 venlafaxine Drugs 0.000 title claims abstract description 40
- 238000013268 sustained release Methods 0.000 title claims abstract description 29
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 47
- 229920000642 polymer Polymers 0.000 claims abstract description 34
- 239000006185 dispersion Substances 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 239000002245 particle Substances 0.000 claims abstract description 21
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 239000011248 coating agent Substances 0.000 claims abstract description 9
- 238000000576 coating method Methods 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 230000008569 process Effects 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 61
- 229960002416 venlafaxine hydrochloride Drugs 0.000 claims description 25
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000011230 binding agent Substances 0.000 claims description 18
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 17
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 17
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 16
- 229920002678 cellulose Polymers 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 10
- 239000001913 cellulose Substances 0.000 claims description 10
- 235000010980 cellulose Nutrition 0.000 claims description 10
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 10
- 239000011118 polyvinyl acetate Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 235000013681 dietary sucrose Nutrition 0.000 claims description 9
- 229960004793 sucrose Drugs 0.000 claims description 9
- 239000004014 plasticizer Substances 0.000 claims description 8
- 239000000454 talc Substances 0.000 claims description 8
- 229910052623 talc Inorganic materials 0.000 claims description 8
- 239000001856 Ethyl cellulose Substances 0.000 claims description 7
- 229920001249 ethyl cellulose Polymers 0.000 claims description 7
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000007771 core particle Substances 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 5
- 239000001069 triethyl citrate Substances 0.000 claims description 5
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 5
- 235000013769 triethyl citrate Nutrition 0.000 claims description 5
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000007900 aqueous suspension Substances 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- 238000000151 deposition Methods 0.000 claims 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 229920002959 polymer blend Polymers 0.000 claims 1
- 229940116351 sebacate Drugs 0.000 claims 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 claims 1
- 239000010410 layer Substances 0.000 description 45
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000008188 pellet Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
- 238000000634 powder X-ray diffraction Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007970 homogeneous dispersion Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 229940044613 1-propanol Drugs 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960005335 propanol Drugs 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- -1 compound venlafaxine hydrochloride Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 229920003164 Eudragit® NE 40 D Polymers 0.000 description 1
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940098766 effexor Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000013563 matrix tablet Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 239000013047 polymeric layer Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004036641A DE102004036641A1 (de) | 2004-07-28 | 2004-07-28 | Verzögert freisetzende pharmazeutische Zusammensetzung, die Venlafaxin enthält |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200701554B true ZA200701554B (en) | 2008-05-28 |
Family
ID=35106687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200701554A ZA200701554B (en) | 2004-07-28 | 2007-02-22 | Sustained release pharmaceutical particulate compositio comprising venlafaxine |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1778193B1 (hr) |
AT (1) | ATE381925T1 (hr) |
CY (1) | CY1107187T1 (hr) |
DE (2) | DE102004036641A1 (hr) |
DK (1) | DK1778193T3 (hr) |
EA (1) | EA009957B1 (hr) |
ES (1) | ES2299061T3 (hr) |
HR (1) | HRP20080007T3 (hr) |
NO (1) | NO20071139L (hr) |
PL (1) | PL1778193T3 (hr) |
PT (1) | PT1778193E (hr) |
RS (1) | RS50572B (hr) |
SI (1) | SI1778193T1 (hr) |
UA (1) | UA83437C2 (hr) |
WO (1) | WO2006010605A2 (hr) |
ZA (1) | ZA200701554B (hr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10722458B2 (en) * | 2011-12-02 | 2020-07-28 | Pegasus Laboratories, Inc. | Amphipathic lipid-based sustained release compositions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL146462A (en) * | 2001-11-13 | 2015-02-26 | Lycored Bio Ltd | Prolonged-release preparations containing as an active compound and analapaxin hydrochloride |
WO2003055475A1 (en) * | 2002-01-03 | 2003-07-10 | Lek Pharmaceutical And Chemical Company D.D. | Controlled release pharmaceutical formulation containing venlafaxine |
CN1674877A (zh) * | 2002-06-07 | 2005-09-28 | 兰贝克赛实验室有限公司 | 控释的多单位药物释放系统 |
EP1572160A2 (en) * | 2002-11-28 | 2005-09-14 | Themis Laboratories Private Limited | Process for manufacturing sustained release microbeads containing venlafaxine hci |
-
2004
- 2004-07-28 DE DE102004036641A patent/DE102004036641A1/de not_active Withdrawn
-
2005
- 2005-07-27 DE DE602005004033T patent/DE602005004033T2/de active Active
- 2005-07-27 SI SI200530187T patent/SI1778193T1/sl unknown
- 2005-07-27 UA UAA200700846A patent/UA83437C2/uk unknown
- 2005-07-27 ES ES05768606T patent/ES2299061T3/es active Active
- 2005-07-27 PT PT05768606T patent/PT1778193E/pt unknown
- 2005-07-27 DK DK05768606T patent/DK1778193T3/da active
- 2005-07-27 RS RSP-2008/0116A patent/RS50572B/sr unknown
- 2005-07-27 EA EA200700159A patent/EA009957B1/ru not_active IP Right Cessation
- 2005-07-27 PL PL05768606T patent/PL1778193T3/pl unknown
- 2005-07-27 AT AT05768606T patent/ATE381925T1/de active
- 2005-07-27 EP EP05768606A patent/EP1778193B1/en active Active
- 2005-07-27 WO PCT/EP2005/008149 patent/WO2006010605A2/en active Application Filing
-
2007
- 2007-02-22 ZA ZA200701554A patent/ZA200701554B/en unknown
- 2007-02-28 NO NO20071139A patent/NO20071139L/no not_active Application Discontinuation
-
2008
- 2008-01-09 HR HR20080007T patent/HRP20080007T3/hr unknown
- 2008-02-13 CY CY20081100161T patent/CY1107187T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE381925T1 (de) | 2008-01-15 |
UA83437C2 (uk) | 2008-07-10 |
EP1778193B1 (en) | 2007-12-26 |
HRP20080007T3 (hr) | 2008-01-31 |
DE102004036641A1 (de) | 2006-03-23 |
EP1778193A2 (en) | 2007-05-02 |
WO2006010605A3 (en) | 2006-09-21 |
EA009957B1 (ru) | 2008-04-28 |
WO2006010605A2 (en) | 2006-02-02 |
ES2299061T3 (es) | 2008-05-16 |
CY1107187T1 (el) | 2012-10-24 |
SI1778193T1 (sl) | 2008-06-30 |
PT1778193E (pt) | 2008-03-10 |
RS50572B (sr) | 2010-05-07 |
DK1778193T3 (da) | 2008-02-04 |
DE602005004033D1 (de) | 2008-02-07 |
EA200700159A1 (ru) | 2007-06-29 |
NO20071139L (no) | 2007-02-28 |
DE602005004033T2 (de) | 2009-01-02 |
PL1778193T3 (pl) | 2008-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8557282B2 (en) | Extended release compositions comprising as active compound venlafaxine hydrochloride | |
US7807195B2 (en) | Extended release formulation of venlafaxine hydrochloride | |
HU226582B1 (en) | New controlled release bead, a method of producing the same and multiple unit formulation comprising it | |
US20070202172A1 (en) | Metoprolol succinate E.R. tablets and methods for their preparation | |
EP1928424B1 (en) | Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof | |
US20090175935A1 (en) | Pharmaceutical compositions of duloxetine | |
US20090017111A1 (en) | Tolterodine bead | |
US20070248670A1 (en) | Tolterodine beads | |
US20080050449A1 (en) | Controlled release formulation of tolterodine | |
US20070275066A1 (en) | Sustained release drug delivery system composed of water insoluble polymer | |
EP1778193B1 (en) | Sustained release pharmaceutical particulate composition comprising venlafaxine | |
US20080118554A1 (en) | Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant | |
RU2727721C2 (ru) | Фармацевтическая композиция с замедленным высвобождением, содержащая ривастигмин | |
WO2009121178A1 (en) | Novel oral controlled release pharmaceutical formulations | |
US20090175934A1 (en) | Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same | |
WO2005016317A1 (en) | Process for manufacture of extended release pellets containing diltiazem hci | |
KR20060136409A (ko) | 벤라팍신 히드로클로라이드의 방출연장형 코팅 미니정제 |